ImpediMed Ltd
ASX:IPD
ImpediMed Ltd
Revenue
ImpediMed Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImpediMed Ltd
ASX:IPD
|
Revenue
AU$11.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Revenue
AU$27.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Cochlear Ltd
ASX:COH
|
Revenue
AU$2.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Revenue
AU$1.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
31%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Revenue
AU$58.2m
|
CAGR 3-Years
21%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Revenue
AU$8.6m
|
CAGR 3-Years
76%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
What is ImpediMed Ltd's Revenue?
Revenue
11.5m
AUD
Based on the financial report for Dec 31, 2024, ImpediMed Ltd's Revenue amounts to 11.5m AUD.
What is ImpediMed Ltd's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for ImpediMed Ltd have been 5% over the past three years , 17% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet